Drug Management of Prostate Cancer

1. Cell Biology of Prostate Cancer and Molecular Targets
Martin E. Gleave, Michael E. Cox, Yuzhuo Wang

2. Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer
Andrew V. Schally, Norman L. Block

3. Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer
Hannelore V. Heemers, Donald J. Tindall

4. Androgens and Prostate Cancer
Douglas K. Price, Ann W. Hsing

5. Androgen Receptor Biology in Prostate Cancer
Edward P. Gelmann

6. Androgen Receptor Antagonists
Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk

7. 5-Alpha Reductase Inhibitors in Prostate Cancer
Zoran Culig

8. Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer
Terence W. Friedlander, Charles J. Ryan

9. Androgen Deprivation Therapy
Nima Sharifi

10. Pharmacogenetics of the Androgen Metabolic Pathway
Francine Zanchetta Coelho Marques, Juergen K. V. Reichardt

11. Mitoxantrone
Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman

12. Docetaxel
Courtney K. Phillips, Daniel P. Petrylak

13. Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer
Jonathan Rosenberg

14. Platinum Agents in Prostate Cancer
Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh

15. Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer
Tristan M. Sissung, William D. Figg

16. Microtubule Targeting Agents
Antonio Tito Fojo, David E. Adelberg

17. Principles of Antiangiogenic Therapy
Cindy H. Chau, William D. Figg

18. Bevacizumab in Advanced Prostate Cancer
Aymen A. Elfiky, William Kevin Kelly

19. Thalidomide and Analogs
Erin R. Gardner, Giuseppe Lorenzo, William D. Figg

20. Investigational Angiogenesis Inhibitors
Jeanny B. Aragon-Ching, William Dahut

21. Pharmacogenetics of Angiogenesis
Guido Bocci, Giuseppe Pasqualetti, Antonello Paolo, Francesco Crea, Mario Tacca, Romano Danesi

22. Pathophysiology of Prostate Cancer Bone Metastasis
Evan T. Keller, Christopher L. Hall

23. Radiopharmaceuticals
Oliver Sartor, Damerla R. Venugopal

24. Bisphosphonates for Prevention and Treatment of Bone Metastases
Philip J. Saylor, Matthew R. Smith

25. Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer
Joel B. Nelson

26. Calcitriol and Vitamin D Analogs
Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas

27. Cancer Immunology, Immunotherapeutics, and Vaccine Approaches
Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom

28. Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer
Celestia S. Higano

29. GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX
Lalit R. Patel, Jonathan W. Simons

30. CTLA-4 Blockade for Prostate Cancer Treatment
Andrea L. Harzstark, Lawrence Fong

31. Prostate Cancer Chemoprevention Strategies
Howard L. Parnes, Margaret G. House, Joseph A. Tangrea

32. Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk
June M. Chan, Erin L. Richman

33. Inflammation as a Target in Prostate Cancer
Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. Marzo

34. Challenges for the Development of New Agents in Prostate Cancer
Ajjai S. Alva, Deborah A. Bradley, Maha Hussain

35. FDA Approval of Prostate Cancer Treatments
Yang-Min Ning, Ramzi N. Dagher, Richard Pazdur

36. Applications of Proteomics in Prostate Cancer
Mitchell Gross, Edward Macrohon Nepomuceno, David B. Agus

Nyckelord: Medicine & Public Health, Oncology, Urology/Andrology, Internal Medicine